Safety Related to the Timing of Radiotherapy and Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer: A Single Institutional Experience

Background: The safety impact of radiotherapy (RT) timing relative to immune checkpoint inhibitors (ICIs) for advanced non-small-cell lung cancer (NSCLC) is unclear. We investigated if RT within 14 days (Interval 1) and 90 days (Interval 2) of ICI use is associated with toxicities compared to RT out...

Descripción completa

Detalles Bibliográficos
Autores principales: Tjong, Michael C., Ragulojan, Malavan, Poon, Ian, Louie, Alexander V., Cheng, Susanna Y., Doherty, Mark, Zhang, Liying, Ung, Yee, Cheung, Patrick, Cheema, Parneet K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8775081/
https://www.ncbi.nlm.nih.gov/pubmed/35049695
http://dx.doi.org/10.3390/curroncol29010021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8775081/
https://www.ncbi.nlm.nih.gov/pubmed/35049695
http://dx.doi.org/10.3390/curroncol29010021

Ejemplares similares